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Abstract
Background: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This
study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea.
Methods: CHB infection was simulated using a health-state transition model with disease states defined as mild disease
(Ishak F0/F1), fibrosis (F2/F3/F4), advanced fibrosis/cirrhosis (.F4), and complicated disease states (decompensated
cirrhosis, hepatocellular carcinoma, liver transplant and death) based on available natural history data. The value of
treatment-specific attributes on disease progression/regression was estimated based on published data in terms of events
and costs avoided. 5-year treatment duration was assumed except for treatment initiation. Primary model output is the
estimated cost savings of entecavir per patient per day of treatment versus the comparator in question for a given CHB
patient.
Results: The simulation of treating with entecavir versus no treatment predicted improved clinical outcomes for entecavir-
treatment patients. In the long term, these clinical benefits translate into cost savings of $3.10 per day of treatment. In naive
patient treatment, daily cost savings of using entecavir versus lamivudine or telbivudine was estimated at $2.89 and $1.72,
respectively. In the case of suboptimal responders who pre-treated with lamivudine, daily cost saving for patients switching
to entecavir was $1.38 per day of treatment compared to patients maintaining on lamivudine.
Conclusions: Entecavir exhibits characteristics of a favourable CHB treatment, which directly translates into economic and
therapeutic value as opposed to either no treatment or alternative strategies.
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Introduction
Chronic hepatitis B (CHB) is an infectious disease caused by
hepatitis B virus (HBV). If not successfully treated, CHB can lead
to progressive liver damages, including cirrhosis, hepatocellular
carcinoma (HCC) and death [1]. Approximately 2 billion people
worldwide are infected with HBV and more than 350 million have
chronic hepatitis B (CHB) infection (WHO 2010). Although the
incidence of HBV infection has been decreasing in Korea, in part
because of vaccination strategies and improved socio-economic
conditions [2], large number of patients is still affected. In Korea,
the incidence of reported hepatitis B cases per 100,000 inhabitants
in 2010 was 290 (market report by Synovate 2010). The risk of
cirrhosis and HCC is also higher in patients who had persistently
high levels of HBV replication (high viral load) and long durations
of active hepatitis. These states of the disease are associated with
an increased risk of morbidity and mortality, and incur
considerable healthcare costs. Treatment for chronic hepatitis B
aims to prevent or reduce morbidity and mortality associated with
cirrhosis and HCC. It can be achieved with the eradication of
HBV infection or clearance of serum HBsAg, but rarely with
current antiviral treatment. The more realistic goal is to maintain
suppression of HBV replication at the lowest possible level. Several
studies have shown that inhibition of viral replication is associated
with remission of liver disease and prevention of HBV related
complication. Recently, seven therapeutic agents have been
approved for treatment of chronic hepatitis B patient. Among
these, entecavir, lamivudine, and telbivudine are the most widely
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used antiviral agents in Asia Pacific region including Korea, where
tenofovir is not yet available. Optimal antiviral therapy that
induces sustained suppression of HBV replication can modify the
natural history of chronic HBV infection [3], thereby reducing the
human and financial costs of this disease [4,5]. The latest CHB
treatment guidelines by APASL (Asian Pacific Association for the
Study of the Liver Disease) recommend the use of potent antiviral
drugs with high genetic barrier. However, these recommendations
do not take into consideration treatment cost or therapy
monitoring. In fact, the increased financial burden of CHB
healthcare requires physicians, payors, and healthcare decision-
makers to evaluate the cost-effectiveness of therapy [6,7]. The
benefit of treating CHB patients according to guidelines can be
measured by the value of avoiding the costs associated with disease
progression.
A perceived value assessment (PVA) model was employed to
analyze the long-term impact of CHB treatment scenarios in
Korea, aiming to shed light on the relative economic value of each
antiviral therapy. The PVA model attempts to capture the long-
term complications and effects of treatment through the use of a
multilayered Markovian model. The PVA methodology is
consistent with a cost-benefit analysis, where the clinical benefits
of treatment-occurrence of histological improvement and CHB
disease regression, avoidance of resistance, avoidance of renal
adverse events, avoidance of additional monitoring requirements-
are expressed in monetary terms. The PVA method differs from
conventional health economics analysis in that it is designed to
disaggregate economic values, each value linked to the aforemen-
tioned clinical benefits. The primary output is cost-avoidance
against a chosen therapy option, with discrete breakdown by cost-
differentiating clinical attribute. We report PVA analysis on
available CHB treatment options at treatment initiation, naive
patient treatment and suboptimal switch treatment. The results
are illustrated as comparison against entecavir, the most potent as
well as the most expensive NA antiviral therapy in the market.
Materials and Methods
Treatment options
Long-term clinical and economic evaluation of entecavir was
compared against various treatment regimes (Figure 1), including
1) treatment initiation (entecavir treatment vs. no treatment), 2)
naive patient treatment, compared with lamivudine (100 mg/day),
and telbivudine (600 mg/day), 3) management of suboptimal
responders who were pre-treated with, but did not develop
resistance to, lamivudine for at least 1 year (switch to entecavir vs.
maintain on lamivudine).
Modelling
To capture the long-term complications and effects of CHB
treatment with entecavir, and other available antiviral agents
(lamivudine and telbivudine), a model was developed with two
distinct but interlinked components. A multilayered Markovian
model (disease state transition model) was used to simulate the
natural progression of hepatitis B and the effect of treatment. This
was combined with a detailed cost calculator for all components in
the natural history model and each treatment option.
The main model used four (two-by-two combination) states
determined by combinations of treatment response (controlled/
uncontrolled viral load) and drug resistance (yes/no). A controlled
viral load state indicates HBV DNA level of,300 copies/ml in all
treatment options. All patients started in model with uncontrolled
viral load. Within each of the four combinations of treatment
response and drug resistance, a sub-model was designed around
CHB disease states based on available natural history data and end
states that the patients progressed through (Figure 2). The natural
progression rate through these states was dependent on viral load
status, being faster with uncontrolled viral load, and used a
weighted ‘uncontrolled’ viral load average disease progression
based on results of the REVEAL study [8,9]. Progression through
Ishak fibrosis stages F2–F4 was modelled using the data from the
analysis of Veenstra et al. and calibrated using the REVEAL study
[9,10]. REVEAL study was selected because of its long-term
observation period extending over 13 years among Asian subset,
while Veenstra analysis was selected because no Asian subset
studies were available with such uniquely large patient number.
Rates of progression to end-states were estimated using clinical
trial data [10]. Mortality due to severe CHB disease states was
based on the published evidence [4,10–13], whereas mortality
rates similar to the general population of any country were
assumed for less severe CHB disease states (F0/F1, F2/F3/F4,
HBeAg seroconversion, HBsAg loss).
Time horizon
Events and costs were modeled over a time horizon of 30 years
in yearly cycles, with the base case treatment duration of 5 years.
The 5-year treatment includes all treatment costs associated with
salvage therapy for patients who have developed resistance and/or
adverse events. Patients reaching treatment endpoints such as
HBeAg seroconversion do not incur treatment cost during this
period. For the 25-year calculation, only management costs
associated with disease progression are incorporated.
PVA analysis relies on the availability and extent of solid clinical
data. However, most clinical data are available for 5 or 6 years at
most, not as long as the 30 years of simulation period. This is a key
reason for the 5-year treatment duration and 25-year follow-up
time horizon of the analysis. For the purpose of simulation across
all comparisons, we assumed that the 5-year end-state patient
clinical status is preserved at sustained viral load suppression and
resistance until year 30.
Patient population
Patient population at baseline was set to most closely reflect the
average Korean population. Utilizing the data available, the
hypothesized average values were validated through an expert
panel and tested through sensitivity analyses. The patient
population is comprised of cohorts of 1,000 hypothetical hepatitis
B e antigen (HBeAg)-positive and HBeAg-negative, CHB patients
for each treatment group. The ratio of HBeAg-positive to negative
patients for model results is 60% to 40% (Adapted from Kim et al.
2010 KASL, originally 56%:44%) [2]. The percentage of those
entering the model in ‘cirrhosis’ state was assumed to be 17% [2].
All other individuals are assumed to start in ‘F2/F3/F4’ state.
Patients with an Ishak fibrosis score F0/F1 were assumed not to
initiate treatment (APASL treatment guidelines and guidance from
key opinion leaders)
Analysis of disease progression was separately run for the
HBeAg-positive and negative CHB patient population. Results
could be produced for either population, with the model defaulting
to an average of the two populations. Average age of CHB
treatment patients was assumed to be 35 years at treatment
initiation, regardless of HBeAg status.
Clinical & mortality input
Viral load suppression data were taken from pivotal trials for
lamivudine [14–19], telbivudine [19–21], entecavir [17,18,22,23].
For switch to entecavir of suboptimal responders for lamivudine,
Heo et al. data was mainly utilized [24].
Modelling the Impact of Entecavir on CHB
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It was assumed that reversal of fibrosis did not occur while off-
treatment or under uncontrolled viral load (HBV DNA
.300 copies/ml). For the comparison with no treatment, the
entecavir histological improvement rate was based on 6-year trial
data of $1 score improvement on the Ishak scale [25]. For the
comparison with other antiviral therapies, histological improve-
ment rate was assumed that it is solely dependant on the
percentage of controlled population. The histological improve-
ment rate of each treatment was calculated based on the annual
probability of entecavir and controlled population. Long-term
resistance data was also taken from pivotal trials for lamivudine,
telbivudine, and entecavir [26–28]. For suboptimal switch to
entecavir, Heo et al. was utilized [24]. Study assumptions were
summarised in Table 1. Mortality due to severe CHB disease state
Figure 1. Treatment Options. (1) Treatment option showing comparison between treatment with entecavir versus no treatment, (2i) In naive
patient treatment, comparison between treatment with lamivudine versus with entecavir, (2ii) comparison between treatment with telbivudine
versus entecavir, (3) In suboptimal responders who pre-treated with lamivudine for a least 1 year without YMDD resistance, comparison between
maintained on lamivudine versus switched to entecavir (1 mg).
doi:10.1371/journal.pone.0057900.g001
Figure 2. Model sub-structure. Single arrows represent transitions between health states; looped arrows indicates situations where transition out
of a particular disease state is not 100% (i.e. a patient may remain in the disease state); wide arrows represent transitions to or from any state in the
central green column to a specific disease/end state. Chronic hepatitis B disease states are based on Ishak fibrosis scores: F0/F1 (mild disease), F2/F3/
F4 (fibrosis), .F4 (advanced fibrosis/compensated cirrhosis), decompensated cirrhosis, hepatocellular carcinoma, liver transplant, post-liver
transplant. Adverse events/other dynamic disease states include HBsAg loss, HBeAg seroconversion, creatine kinase elevationThe end state is death.
doi:10.1371/journal.pone.0057900.g002
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(Decompensated cirrhosis, HCC) was considered in the model
based on published evidence [4,9–13]. For less severe CHB disease
states (fibrosis) mortality rates similar to the general population
were assumed. Inputs for mortality rates can be also found in
Table 1.
Cost inputs
The model assumed that each disease state has associated cost of
care. This study only considers direct healthcare cost such as the
cost related to diagnosis of the treatment, laboratory testing, drugs,
follow-up and disease complication. Drug costs were taken from
the database from HIRA (Health Insurance Review & Assessment
Service in Korea). Disease complication costs were updated using
current clinical practice and HIRA data [29] (Table 2). The
analysis was performed from the perspective of national health
system. For management of resistance, the additional treatment
cost was considered; including clinical assays for mutant detection
as well as the salvage therapy cost.
For drug-related adverse events, the model assumed that safety
and tolerability of entecavir were similar to those of lamivudine
and the drug has no requirement for renal monitoring (Entecavir
SPC 2009). However, patients receiving telbivudine may be at the
risk of the elevation of creatine kinase concentration that requires
additional monitoring and treatment. Specifically telbivudine
requires additional creatinine clearance/serum phosphate test
during the treatment period [30,31].
Costs were calculated to net present value at an annual discount
rate of 5%, according to HIRA guideline recommendations. All
costs were inflated to 2010 prices using Korea health-specific
consumer-prices indices. All costs were calculated from the holistic
point of view, with both patients’ out-of-pocket cost and payor’s
cost in consideration.
Model outputs
The primary outcome measures were per-patient cost per day of
treatment of entecavir compared with no treatment or other
antiviral therapies over a time horizon of 30 years assuming 5-year
duration of treatment. The daily overall treatment cost was based
on drug acquisition cost and clinical differences between treatment
options. In comparison with no treatment, clinical events
Table 1. Model Assumption.
Variables Baseline Value, % Reference
Baseline characteristics
HBeAg-postivie: HBeAg-negative (% of population) 60%:40% [2]
Ishak fibrosis stage F2,F4: .F4a 83%:17% [2]
Treatment compliance rate 74%b [38]
Annual discount rate 5%b HIRA 2010
Annual disease progression rates – HBeAg-positive and –negative (unconrolled : controlled viral load)
Progression from F0/F1 to F2/F3/F4 0.5%c:0.0%d [9,10]
Progression form F2/F3/F4 to .F4/cirrhosis 7.0%c:1.9%d [9,10]
Progression from.F4/cirrhosis to decompensated cirrhosis 3.1%c:0.8%d [9,10]
Progression from decompensated cirrhosis to liver transplant 2.6%c:0.7%d [9,10]
Progression from liver transplant to post liver transplant 100.0%c:100.0%d Assumption
Progression from HCC to liver transplant 30.0%c:30.0%d [10]
F0/F1 to HCC 0.5%c:0.1%d [11]
F2/F3/F4 to HCC 1.0%c:0.2%d [9]
.F4/cirrhosis/advanced fibrosis to HCC 2.2%c:2.2%d [11]
Decompensated.F4 /cirrhosis/advanced fibrosis to HCC 2.2%c:2.2%d [11]
Annual death rates
Year 1 to 30(Age 35 to 64)e 0.1–1.19% WHO 2009
.F4/cirrhosis/advanced fibrosis to death 4.9%e [12]
Decompensated.F4/cirrhosis/advanced fibrosis to death 19.0%e [4]
HCC to death 23.0%e [9,10]
Liver transplant to death 13.0%e [13]
Post-liver transplant to death 2.5%e [13]
Annual histological improvement rates - on treatment – HBeAg-positive and –negative (uncontrolled:controlled viral load)
Improvement from F2/F3/F4 to F0F1 0.0%c:18.5%d [25]
Improvement from .F4 /cirrhosis/advanced fibrosis to F2/F3/F4 0.0%c:20.0%d [25]
aNo patients entered the model in Ishak fibrosis stages F0/F1 or decompensated cirrhosis/HCC/liver transplant/post-liver transplant.
bSensitivity analysis input range for compliance rate 70%,90%, for annual discount rate 3%,7%, and for all other variables 610% standard deviation.
cPatients with uncontrolled viral load (HBV DNA level.300 copies/ml).
dPatients with controlled viral load (HBV DNA level ,300 copies/ml).
eAssumptions for the population as a whole. The probability of death was linked to liver histology and not to viral load.
HBeAg =hepatitis B e antigen; HBsAg = hepatitis B surface antigen, HBV =hepatitis B virus, HCC= hepatocellular carcinoma; CHB= chronic hepatitis B; HIRA=Health
Insurance Review & Assessment Service in Korea
doi:10.1371/journal.pone.0057900.t001
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considered were HBsAg loss, HBeAg seroconversion, fibrosis,
cirrhosis, decompensated cirrhosis, HCC, liver transplantation
and post-liver transplantation. In comparison with other antiviral
therapies, clinical attributes considered were long term slowing of
disease progression and reversal of liver fibrosis/cirrhosis, high
genetic barrier and long-term resistance, for which additional
monitoring and pharmacotherapy cost, and related adverse events
cost are avoidable.
Costs avoided for each of the clinical events listed above over
the 30 year follow-up period were calculated for use of entecavir
compared with no treatment or other antiviral therapies and then
re-calculated to estimate the ‘cost saving per day of treatment’ (cost
saving/total days on treatment). Costs avoided were calculated for
each event type avoided as (total number of events avoided6cost
of event/days on treatment). The resultant costs were applied to
the daily dose acquisition cost for each treatment to determine the
true cost of entecavir relative to no treatment or other antiviral
therapies for which the model was run. In this manuscript, costs
are presented in 2010 values and as the proportion of entecavir
acquisition cost saved by use of entecavir relative to the
comparators. In this analysis, we assume that 1 USD is equal to
1,000 KRW.
Sensitivity analyses
Both univariate and multivariate analyses were conducted to
test the robustness of model outcome, given the uncertainty
around certain clinical and cost inputs. The univariate analysis
investigated the effects of varying one key input at a time and then
ranked the influence of each variable, and the multivariate analysis
investigated the effects of varying all variable inputs simultaneous-
ly. The analyses results were used to identify the key inputs
generating the biggest variation in model outputs. These inputs,
along with other key inputs with some uncertainty, were
subsequently used for probabilistic sensitivity analyses. Discount
rate, all unit costs and disease state costs, clinical profiles including
virologic suppression efficacy and resistance, baseline character-
istics such as HBeAg positive to negative ratio, and compliance
rate were among the key input variables that were tested.
Results
Entecavir vs. No Treatment
If CHB is untreated, the disease can progress to serious
complications such as decompensated cirrhosis, HCC, and even
death. Optimal antiviral treatment can slow down, or even
reverse, the disease progression through effective and sustained
virologic suppression, long-term protection against resistance to
treatment, and long-term safety with low incidence of associated
adverse events. Entecavir exhibits the optimal profile in all clinical
aspects among CHB antiviral NA therapies available in Korea.
This observation coincides with the patient distribution compar-
isons after the modelling period. Simulation of disease progression
over 30 years showed that, when patients were not treated, death,
liver transplantation, or HCC occurred in 75% of the patients by
year 30; advanced fibrosis/cirrhosis or decompensated cirrhosis
developed in 13%; and 12% remained in stages F0 to F4 fibrosis
(Figure 3A). On the other hand, for entecavir treated patients,
34%, 7% and 59% of the patients ended in serious, medium and
mild stages, respectively (Figure 3A). In other words, treatment
with high genetic barrier antiviral therapy significantly reduced
disease progression in CHB natural history. Saving in CHB
management-related costs over the patients’ lifetime achieved by
using entecavir was $8.98, which fully outweighed the acquisition
cost of the drug ($5.88). This indicates the use of entecavir instead
of no treatment achieved daily saving of $3.10 (95% confidence
interval: $2.10,$3.76).
Table 2. Model Cost Input.
Variables Cost (USD) Source
Disease state costa
F0/F1 339b [29], Updated based on Yang et al. 2010 with HIRA 2009 data
F2/F3/F4 373b [29], Updated based on Yang et al. 2010 with HIRA 2009 data
.F4 advanced fibrosis/compenstated cirrhosis 702c [29], Updated based on Yang et al. 2010 with HIRA 2009 data
Decompensated cirrhosis 1,474 c [29], Updated based on Yang et al. 2010 with HIRA 2009 data
Liver transplantation 78,684d KONOS (Korean Network for Organ Sharing) database
Post liver transplantation 11,697 d KONOS (Korean Network for Organ Sharing) database
HBsAg loss 170e [29], Updated based on Yang et al. 2010 with HIRA 2009 data
Hepatocellular carcinoma 5,224 [29], Updated based on Yang et al. 2010 with HIRA 2009 data
Death 0f -
Antiviral treatment cost per pill
Entecavir 5.88 HIRA 2010
Lamivudine 3.26 HIRA 2010
Telbivudine 3.35 HIRA 2010
aAntiviral drug cost not included
bCalculated from fibrosis total cost, assuming F0F1/:F2F3F4= 1:1.1 based on guidance of Korean advisory board, In addition, patient ratio is assumed to 1:1
cCalculated from cirrhosis total cost, assuming compensated: decompensated = 1:2.1 and patient ratio is assumed to be 1:1.61 based on Yang et al. 2004
dCalculated & updated liver transplant surgery cost & post liver transplant cost with Korea organ sharing networks database & Seoul national university organ transfer
center data base
eAssume about 50% of F0/F1 based on EASL guideline
fOnly consider direct medical cost of caring disease state
doi:10.1371/journal.pone.0057900.t002
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Entecavir vs. Lamivudine or Telbivudine
When costs relating to long-term virological suppression rate,
treatment of resistance, and drug-related toxicity for entecavir
relative to lamivudine or telbivudine were taken into consider-
ation, the difference in acquisition cost was more than offset by
costs avoided with the use of entecavir (Figure 3B). Daily
acquisition cost of lamivudine and telbivudine is $3.26 and $
3.35, respectively. When considering the clinical benefit of
entecavir, such as long-term virological suppression and high
genetic resistance, the use of entecavir represented daily cost
saving of $2.89 (95% confidence interval: $2.10,$3.73). In the
case of comparison between entecavir and telbivudine, the daily
cost saving of entecavir compared to telbivudine was $1.72 (95%
confidence interval: $21.84,$2.30) due to superior clinical profile
of entecavir in terms of virological suppression rate, high genetic
barrier, and long-term safety.
Switch to entecavir vs. maintain on lamivudine for
suboptimal responders for lamivudine
In this analysis, 1 year lamivudine use was included into model
treatment duration, and then it was assumed that only suboptimal
responders who did not develop lamivudine resistance among total
population, (38.4% of total simulation population, which is
weighed-averaged of 60% HBeAg positive and 40% HBeAg-
negative population) were switched to entecavir or maintained on
lamivudine. For 30-year simulation period, the switch to entecavir
group represented daily $1.38 (95% confidence interval:
$0.64,$1.71) cost saving compared to the maintained-on
lamivudine (Figure 3C).
Sensitivity analysis
Sensitivity analyses were conducted to assess the result
robustness across different variables. Multivariate sensitivity
analysis as well as univariate sensitivity analysis indicated that
the annual number of pills taken (dosage compliance rate) was the
most sensitive variable, above discount rate, clinical inputs, cost
inputs, or any other inputs. Entecavir remained cost saving despite
a610% variance in pill count (in comparison with no treatment,
daily cost saving were $3.76 when pill count was reduced by 10%
and $2.10 when pill count went up by 10% from the default value
of 270 pills per year).
Discussion
The largest number of Korean patients infected with HBV was
exposed to major health risks and high financial burdens, not to
mention the subsequent development of cirrhosis and HCC
[32,33]. Lamivudine, telbivudine, and entecavir are the three
major oral agents currently used in Korea for the treatment of
chronic HBV infection. As these treatment options often require
long-term use, the cost of these options should be taken into
account when formulating recommendations. There are several
guidelines regarding various options for CHB treatment, but they
do not consider the cost-effectiveness/benefit of these therapies.
Therefore, we evaluated the cost benefit of entecavir, the agent
known for its superior clinical profile, compared with the other
available antiviral agents for the treatment of CHB based on a best
available clinical trial data. As tenofovir is not yet available in
Korea, it was excluded from analysis. The results of our analysis
suggest that initiating therapy with high genetic barrier such as
entecavir improves health outcomes in a cost-benefit manner
compared with no treatment or other low genetic barrier antiviral
agents. Our findings were driven by several clinical differentiation
factors: (i) greater viral suppression level, (ii) the higher genetic
barrier in resistance, (iii) the long-term safety. The PVA model
demonstrates how these clinical outcomes translate into economic
value. The PVA model, therefore, allows the economic differen-
tiation based on the identified ‘value drivers’.
In this analysis, considering both the cost of treatment and the
cost saved as a result of treatment with entecavir relative to either
no treatment or treatment with other antiviral agents, entecavir
was shown to be most cost saving in Korea. This is mainly because
of a reduction in the incidence of, and therefore potential costs
incurred by, late-stage liver disease in comparison with compar-
ators.
The simulation of treating with entecavir versus no treatment
predicted improved clinical outcomes for entecavir-treatment
patients over a 30-year time period. Progression to HCC, liver
transplant or death was estimated at 75% for patients without
treatment compared to 34% for patients receiving entecavir;
regression to mild disease states (F0/F1) or fibrosis (F2-F4) was
12% and 59% for these populations, respectively. The cost of not
treating patients with CHB was estimated at $8.98 per day
(average over patient life time). Entecavir treatment was translated
into specific patient benefit in terms of events avoided, with an
estimated cost saving of $3.10 per day of entecavir treatment. In
Korea, CHB is particularly prevalent with approximately 1.4
million patients chronically infected (approximately 3% of total
Korean population). Among them, it is reported that only 10.7%
of patients diagnosed as CHB were appropriately monitored or
treated (Synovate Market Research Korean Study – HBV monitor
and treatment pattern). CHB infection is a significant cause of
morbidity and mortality which is associated substantial amount of
caring cost. Particularly, 70% of liver cancer was caused from
CHB in Korea (Korea ministry of health & welfare 2010). Our
analysis shows that if all untreated patients were assumed to be
treated, approximately $ 1.4 billion of healthcare budget saving
could be expected annually.
According to the recommendation by the Korean Association
for the Study of the Liver, entecavir is preferred to lamivudine and
telbivudine as a naive patient treatment due to its potent viral
suppression and favourable resistance profile. However, entecavir
is one of the most expensive agents in Korea (entecavir $ 5.88,
lamivudine $3.26, telbivudine $3.35). Nonetheless, our economic
Figure 3. Model Output. (A) Simulation of No treatment vs. treatment with entecavir for a Korean CHB population: Model simulation of patient
outcomes at year 30 in two hypothetical Korean cohorts of patients with chronic hepatitis B, 60% of whom were HBeAg-positive. A total of 1000
patients were untreated and 1000 patients received entecavir treatment for 5 years (B) Weighted value differentiations between entecavir versus
lamivudine or telbivudine: Daily cost savings per patient with chronic hepatitis B (60% with HBeAg-positive CHB) in Korea over a 30-year period by
use of entecavir instead of lamivudine or telbivudine assuming an average patient lifespan of 65 years and an average initiation age of 35 years and 5
years of treatment with 74% compliance (histological reversal stops when treatment stops). Sensitivity analysis was conducted within 95%
Confidence Interval. (C) Weighted value differentiations between switching to entecavir versus maintaining on lamivudine of suboptimal responders
for lamivudine: Daily cost savings per patient with chronic hepatitis B (60% with HBeAg-positive CHB) in Korea over a 30-year period by use of
entecavir instead of maintain on lamivudine assuming an average patient lifespan of 65 years and an average initiation age of 35 years and 5 years of
treatment with 74% compliance (histological reversal stops when treatment stops). Sensitivity analysis was conducted within 95% Confidence
Interval.
doi:10.1371/journal.pone.0057900.g003
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evaluation demonstrates that naive treatment use of entecavir is
the most cost-benefit strategy for managing CHB with nucleosides.
The daily cost savings of using entecavir versus lamivudine and
telbivudine were estimated at $ 2.89 and $ 1.72, respectively, even
considering antiviral acquisition cost.
In our analysis, we also investigated the cost-benefit of switch to
entecavir for lamivudine pre-treated patients. According to the
latest guideline of the Korean Association for the Study of the
Liver, in the case of suboptimal early virological response to
antiviral agent with low genetic barrier, either a switch to another
antiviral agents with higher genetic barrier of resistance or add-on
another antiviral agents with no cross resistance developed is the
recommended treatment of choice. Lamivudine has been known
for its high non-responding rate and resistance rate with 64% and
23%, respectively, in HBeAg-positive patients for 1 year treatment
[17,19]. There are several clinical trials regarding this switch. [34]
The recent study of Heo et al. assessed the efficacy and resistance
rate of switching Korean suboptimal responders from lamivudine
monotherapy to entecavir 1 mg/day [24]. In this analysis, the
switch group showed 61.1% undetectable level of HBV DNA,
while maintain-on group remained 11.4% of undetectable level
within a year. The resistance rate of switch group and maintain-on
group were 0% and 34.4%, respectively, within the same time
period. Based on this clinical trial result, we investigated the
economic value of suboptimal switch. Even considering the
difference in acquisition cost, the switch group showed daily cost
saving of $1.38 compared to maintain-on group. This cost saving
($1.38) was lower than the one in naive patient treatment ($2.89).
Our finding supports the fact that earlier use of more potent drug
with higher virological suppression and genetic barrier is more
economically beneficial than later use.
The current standard for assessing the value of different
treatment options is the cost-effectiveness analysis. Quality-
adjusted life-years (QALYs) are often used in these analyses to
allow comparisons between different treatments and disease states.
Cost-effectiveness analyses involving treatment for CHB include
the studies of Calcagno et al. [35] and Veenstra et al. [10], which
showed entecavir to be cost-effective compared with lamivudine
alone or with adefovir salvage or combination therapy in the US
and Asia Pacific. The study of Lui et al. [36] showed that, in
HBeAg-positive patients, lamivudine roadmap was most cost-
effective. In HBeAg-negative patients, entecavir and tenofovir
monotherapies were more cost-effective than the roadmap models.
However, cost-effectiveness analyses have some limitations as the
clinical benefits of a given treatment for specific patients are
difficult to assess when the output is expressed in QALYs.
Additionally, when thresholds for cost-effectiveness are used, the
actual cost or cost averted for treating a patient with the treatment
choice is unclear. Value-based approaches avoided these limita-
tions as they compared the cost of an intervention to the cost saved
as a result of that intervention relative to another course of action.
This model has been developed as an alternative to cost-
effectiveness analysis to help the healthcare decision makers
evaluate the ‘value for money’ of treating CHB patients with
several antiviral agents available in Korea. The model is robust, as
health economic approaches were leveraged to create a detailed
analysis that holds up under scrutiny and it is based on best
available data. Importantly, the model assumed that optimal
treatment controls viral load and reverses liver fibrosis. In
addition, the model was run over a time period of 30 years
because of the increased risk of progression to long-term
complication, including cirrhosis, decompensated liver disease
and HCC in patients with CHB.
While certainly robust, the model has some limitations. The
model approach neglects the cost of social burden and considers
direct medical costs only. Hence, the lower death rate would
undermine the cost benefits of entecavir since no disease state cost
is assumed for incidence of death (Table 2). Entecavir, a therapy
with a lower death rate, would apparently incur more healthcare
cost and lead to lower cost benefits than one with a higher death
rate. Another limitation of the model, as with the cost-effectiveness
analysis or any other lifelong simulation, is that due to lack of
clinical data that extends beyond 5 to 6 years, the 30 years time
horizon is hypothetically based on 5-year treatment duration and
25-year follow-up duration. Cost benefit becomes more apparent
under long-term observation for chronic cases such as CHB. As
such, the 5-year results were extended to the entire simulation
period. Such practice is common in cost-utility assessment of CHB
[4,13,14,37]. For the purpose of simulating the long-term
economic effect of the 5-year treatment, we assumed that the 5-
year patient end-state virologic status is maintained until year 30
instead of assuming termination of treatment. Thus, viral load
rebound, seroconversion rebound, and other clinical events
associated to treatment termination were disregarded.
In conclusion, economic benefit of each CHB treatment option
has been analyzed by novel cost estimation model. Based upon this
analysis, high genetic barrier antiviral such as entecavir exhibited
the highest cost saving compared to alternative treatment
strategies mainly due to its superior clinical profile, even
considering expensive price point.
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